Next Article in Journal
Hand Preference and Performance in Basketball Tasks
Previous Article in Journal
Genomics of Particulate Matter Exposure Associated Cardiopulmonary Disease: A Narrative Review
Previous Article in Special Issue
NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome
Open AccessReview

Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives

1
Section of Gastroenterology and Hepatology, PROMISE, Policlinico Universitario Paolo Giaccone, Piazza delle Cliniche 2, 90127 Palermo, Italy
2
Department of Precision Medicine, University of Campania Luigi Vanvitelli, via Pansini 5, 80131 Naples, Italy
*
Authors to whom correspondence should be addressed.
Int. J. Environ. Res. Public Health 2019, 16(22), 4334; https://doi.org/10.3390/ijerph16224334
Received: 16 September 2019 / Revised: 1 November 2019 / Accepted: 3 November 2019 / Published: 7 November 2019
The non-alcoholic fatty liver disease (NAFLD) is rapidly becoming the most common cause of chronic liver disease as well as the first cause of liver transplantation. NAFLD is commonly associated with metabolic syndrome (MetS), and this is the most important reason why it is extremely difficult to treat this disease bearing in mind the enormous amount of interrelationships between the liver and other systems in maintaining the metabolic health. The treatment of NAFLD is a key point to prevent NASH progression to advanced fibrosis, to prevent cirrhosis and to prevent the development of its hepatic complications (such as liver decompensation and HCC) and even extrahepatic one. A part of the well-known healthy effect of diet and physical exercise in this setting it is important to design the correct pharmaceutical strategy in order to antagonize the progression of the disease. In this regard, the current review has the scope to give a panoramic view on the possible pharmacological treatment strategy in NAFLD patients. View Full-Text
Keywords: non-alcoholic fatty liver disease; metabolic therapy; metabolic syndrome non-alcoholic fatty liver disease; metabolic therapy; metabolic syndrome
Show Figures

Figure 1

MDPI and ACS Style

Pennisi, G.; Celsa, C.; Spatola, F.; Dallio, M.; Federico, A.; Petta, S. Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives. Int. J. Environ. Res. Public Health 2019, 16, 4334.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop